SCHEMBL4507510

SCHEMBL4507510

CCC(O)c1ccc2[nH]c(NCC3CCN(Cc4cccc5ccccc45)CC3)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 3/20 0.43
OPRK1 P41145 3/20 0.43
ACHE P22303 2/20 0.42
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
OPRL1 P41146 2/20 0.39
PIK3CB P42338 1/20 0.38
GRIN2B Q13224 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
THRB P10828 1/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
SIGMAR1 Q99720 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496674 0.84 ACHE (0.43) OPRM1OPRK1ACHESLC6A4SLC6A3
SCHEMBL4505044 0.83 ACHE (0.42) OPRM1OPRK1ACHEOPRL1PIK3CB
SCHEMBL4497481 0.82 SMN1; SMN2 (0.44) OPRM1OPRK1ACHESLC6A4OPRL1
SCHEMBL4494897 0.82 ACHE (0.43) OPRM1OPRK1ACHEOPRL1PIK3CB
SCHEMBL4509574 0.82 HSD17B10 (0.44) OPRM1OPRK1ACHEOPRL1PIK3CB
SCHEMBL4509816 0.81 OPRM1 (0.43) OPRM1OPRK1ACHESLC6A4SLC6A3
SCHEMBL4502250 0.76 ACHE (0.48) OPRM1OPRK1ACHEOPRL1PIK3CB
SCHEMBL4507517 0.74 ADRB2 (0.34) SLC6A4SLC6A3
SCHEMBL4493806 0.71 ACHE (0.43) OPRM1OPRK1ACHEOPRL1HDAC1
SCHEMBL4514599 0.68 ACHE (0.40) OPRM1OPRK1ACHEOPRL1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517875-B2 Piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-14 US disclosed
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-08 US disclosed
EP-1502916-A1 PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM TEIJIN LIMITED (JP) 2005-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism CCR3, CCR1, CCR4 OPRM1 388/4885OPRK1 306/4885ACHE 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.